[HTML][HTML] SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies
Monoclonal antibodies (mAbs) offer a treatment option for individuals with severe COVID-19
and are especially important in high-risk individuals where vaccination is not an option …
and are especially important in high-risk individuals where vaccination is not an option …
[HTML][HTML] SARS-CoV-2 variants show resistance to neutralization by many monoclonal and serum-derived polyclonal antibodies
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the global
COVID-19 pandemic infecting more than 106 million people and causing 2.3 million deaths …
COVID-19 pandemic infecting more than 106 million people and causing 2.3 million deaths …
In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains
Rapidly emerging SARS-CoV-2 variants jeopardize antibody-based countermeasures.
Although cell culture experiments have demonstrated a loss of potency of several anti-spike …
Although cell culture experiments have demonstrated a loss of potency of several anti-spike …
Enhanced neutralization escape to therapeutic monoclonal antibodies by SARS-CoV-2 omicron sub-lineages
The landscape of SARS-CoV-2 variants dramatically diversified with the simultaneous
appearance of multiple subvariants originating from BA. 2, BA. 4, and BA. 5 Omicron sub …
appearance of multiple subvariants originating from BA. 2, BA. 4, and BA. 5 Omicron sub …
A combination of receptor-binding domain and N-terminal domain neutralizing antibodies limits the generation of SARS-CoV-2 spike neutralization-escape mutants
D Haslwanter, ME Dieterle, AZ Wec, CM O'brien… - Mbio, 2021 - Am Soc Microbiol
Most known SARS-CoV-2 neutralizing antibodies (nAbs), including those approved by the
FDA for emergency use, inhibit viral infection by targeting the receptor-binding domain …
FDA for emergency use, inhibit viral infection by targeting the receptor-binding domain …
Broadly-neutralizing antibodies against emerging SARS-CoV-2 variants
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants
have become a major concern in the containment of current pandemic. The variants …
have become a major concern in the containment of current pandemic. The variants …
Neutralization of SARS-CoV-2 Omicron BA. 2 by therapeutic monoclonal antibodies
H Zhou, T Tada, BM Dcosta, NR Landau - Biorxiv, 2022 - ncbi.nlm.nih.gov
Monoclonal antibody therapy for the treatment of SARS-CoV-2 infection has been highly
successful in decreasing disease severity; however, the recent emergence of the heavily …
successful in decreasing disease severity; however, the recent emergence of the heavily …
Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the global
COVID-19 pandemic. Rapidly spreading SARS-CoV-2 variants may jeopardize newly …
COVID-19 pandemic. Rapidly spreading SARS-CoV-2 variants may jeopardize newly …
Generation of SARS-CoV-2 escape mutations by monoclonal antibody therapy
M Ragonnet-Cronin, R Nutalai, J Huo… - Nature …, 2023 - nature.com
COVID-19 patients at risk of severe disease may be treated with neutralising monoclonal
antibodies (mAbs). To minimise virus escape from neutralisation these are administered as …
antibodies (mAbs). To minimise virus escape from neutralisation these are administered as …
[HTML][HTML] Increased resistance of SARS-CoV-2 variants B. 1.351 and B. 1.1. 7 to antibody neutralization
The Covid-19 pandemic has ravaged the globe, and its causative agent, SARS-CoV-2,
continues to rage. Prospects of ending this pandemic rest on the development of effective …
continues to rage. Prospects of ending this pandemic rest on the development of effective …